Pharmaron eyes bulk DMT production for science: DEA seeks objections
Published Date: 3/26/2025
Notice
Summary
Pharmaron Manufacturing Services (US), LLC wants to become a big-time maker of certain controlled drugs like Dimethyltryptamine and Oxymorphone for clinical trials. If you have thoughts or objections, you’ve got until May 27, 2025, to speak up online or ask for a hearing. This move affects drug makers and researchers and could speed up new medicine testing without extra costs for the public.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Application to Bulk‑Manufacture Three Controlled Drugs
On February 11, 2025, Pharmaron Manufacturing Services (US), LLC (498 Washington Street, Coventry, Rhode Island 02816) applied to be registered to bulk manufacture Dimethyltryptamine (drug code 7435, Schedule I), Oxymorphone (drug code 9652, Schedule II), and Noroxymorphone (drug code 9668, Schedule II). The application requests authorization to act as a bulk manufacturer for these specific drug codes.
Manufacture Limited to Clinical Trial Material
The company states it plans to bulk manufacture the listed substances specifically to produce material for clinical trials, and the registration (if issued) would not authorize any other activities for those drug codes. The notice specifies that no other activities for these drug codes are authorized for this registration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-05054, Bulk Manufacturer of Controlled Substances Application: Sterling Wisconsin, LLC
Sterling Wisconsin, LLC wants to become a big-time maker of some powerful controlled substances like LSD, marijuana extracts, and psilocybin. If you’re involved or interested, you can share your thoughts or ask for a hearing by May 27, 2025. This move could shake up how these substances are produced and handled, so keep an eye on the timeline and get ready to weigh in!
Next: 2025-05056, Importer of Controlled Substances Application: Pharmaron Manufacturing Services (US) LLC
Pharmaron Manufacturing Services (US) LLC wants to become an official importer of certain controlled substances. If you’re a registered manufacturer or interested party, you can share your thoughts or ask for a hearing by April 25, 2025. This move could impact companies dealing with these drugs, but no costs or fees are mentioned yet.